William C Nichols

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7775914/publications.pdf

Version: 2024-02-01

58 papers	7,639 citations	126858 33 h-index	133188 59 g-index
62 all docs	62 docs citations	62 times ranked	7836 citing authors

#	Article	IF	Citations
1	Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension. European Respiratory Journal, 2022, 59, 2002463.	3.1	31
2	Biomarkers of Pulmonary Hypertension Are Altered in Children with Down Syndrome and Pulmonary Hypertension. Journal of Pediatrics, 2022, 241, 68-76.e3.	0.9	3
3	Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in <scp>GBA</scp> Mutation Carriers. Annals of Neurology, 2022, 91, 424-435.	2.8	46
4	Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1449-1460.	2.5	19
5	Bayesian Inference Associates Rare KDR Variants With Specific Phenotypes in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2021, 14, .	1.6	29
6	United States Pulmonary Hypertension Scientific Registry. Chest, 2021, 159, 311-327.	0.4	25
7	Cognitive Functioning of Glucocerebrosidase (GBA) Non-manifesting Carriers. Frontiers in Neurology, 2021, 12, 635958.	1.1	14
8	Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. Genome Medicine, 2021, 13, 80.	3.6	43
9	ST2 Is a Biomarker of Pediatric Pulmonary Arterial Hypertension Severity and Clinical Worsening. Chest, 2021, 160, 297-306.	0.4	6
10	Subthalamic Peak Beta Ratio Is Asymmetric in Glucocerebrosidase Mutation Carriers With Parkinson's Disease: A Pilot Study. Frontiers in Neurology, 2021, 12, 723476.	1.1	5
11	Insulin-like growth factor binding protein-2: a new circulating indicator of pulmonary arterial hypertension severity and survival. BMC Medicine, 2020, 18, 268.	2.3	15
12	Elevated Interleukin-6 Levels Predict Clinical Worsening in Pediatric Pulmonary Arterial Hypertension. Journal of Pediatrics, 2020, 223, 164-169.e1.	0.9	9
13	Pediatric pulmonary hypertension: insulin-like growth factor-binding protein 2 is a novel marker associated with disease severity and survival. Pediatric Research, 2020, 88, 850-856.	1.1	6
14	Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 586-594.	2.5	45
15	Novel Mutations and Decreased Expression of the Epigenetic Regulator TET2 in Pulmonary Arterial Hypertension. Circulation, 2020, 141, 1986-2000.	1.6	75
16	A novel BMPR2Âmutation with widely disparate heritable pulmonary arterial hypertension clinical phenotype. Pulmonary Circulation, 2020, 10, 1-4.	0.8	6
17	Cellular sources of interleukin-6 and associations with clinical phenotypes and outcomes in pulmonary arterial hypertension. European Respiratory Journal, 2020, 55, 1901761.	3.1	48
18	Genetic Admixture and Survival in Diverse Populations with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1407-1415.	2.5	18

#	Article	IF	Citations
19	Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension. European Respiratory Journal, 2020, 55, 1901486.	3.1	26
20	The EYA3 tyrosine phosphatase activity promotes pulmonary vascular remodeling in pulmonary arterial hypertension. Nature Communications, 2019, 10, 4143.	5.8	24
21	Phenotype characterisation of TBX4 mutation and deletion carriers with neonatal and paediatric pulmonary hypertension. European Respiratory Journal, 2019, 54, 1801965.	3.1	77
22	United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications. Pulmonary Circulation, 2019, 9, 204589401985169.	0.8	7
23	Novel risk genes and mechanisms implicated by exome sequencing of 2572 individuals with pulmonary arterial hypertension. Genome Medicine, 2019, 11, 69.	3.6	86
24	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238.	5.2	122
25	Genetics and genomics of pulmonary arterial hypertension. European Respiratory Journal, 2019, 53, 1801899.	3.1	306
26	Exome Sequencing in Children With Pulmonary Arterial Hypertension Demonstrates Differences Compared With Adults. Circulation Genomic and Precision Medicine, 2018, 11, e001887.	1.6	104
27	Tandem mass spectrometry assay of Î²-glucocerebrosidase activity in dried blood spots eliminates false positives detected in fluorescence assay. Molecular Genetics and Metabolism, 2018, 123, 135-139.	0.5	12
28	Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease. Genome Medicine, 2018, 10, 56.	3.6	112
29	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBIâ€"Cardiovascular Medical Research and Education Fund Workshop Report. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1661-1670.	2.5	59
30	Pulmonary arterial hypertension: Specialistsâ€™ knowledge, practices, and attitudes of genetic counseling and genetic testing in the USA. Pulmonary Circulation, 2017, 7, 372-383.	0.8	12
31	Racial and ethnic differences in pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 793-796.	0.8	38
32	Neuropsychiatric characteristics of GBA-associated Parkinson disease. Journal of the Neurological Sciences, 2016, 370, 63-69.	0.3	50
33	Genetic and Clinical Predictors of Deep Brain Stimulation in Youngâ€Onset Parkinson's Disease. Movement Disorders Clinical Practice, 2016, 3, 465-471.	0.8	37
34	Glucocerebrosidase enzyme activity in GBA mutation Parkinsonâ€™s disease. Journal of Clinical Neuroscience, 2016, 28, 185-186.	0.8	33
35	Glucocerebrosidase activity in Parkinsonâ€™s disease with and withoutGBAmutations. Brain, 2015, 138, 2648-2658.	3.7	326
36	Cognitive and Motor Function in Long-DurationPARKIN-Associated Parkinson Disease. JAMA Neurology, 2014, 71, 62.	4.5	49

#	Article	IF	Citations
37	Comparison of Parkinson Risk in Ashkenazi Jewish Patients With Gaucher Disease andGBAHeterozygotes. JAMA Neurology, 2014, 71, 752.	4.5	172
38	Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations. Movement Disorders, 2013, 28, 1966-1971.	2.2	131
39	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. JAMA Neurology, 2013, 70, 727.	4.5	374
40	Genomewide linkage study of modifiers of LRRK2â€related Parkinson's disease. Movement Disorders, 2011, 26, 2039-2044.	2.2	8
41	Copy Number Variation in Familial Parkinson Disease. PLoS ONE, 2011, 6, e20988.	1.1	67
42	Alphaâ€synuclein and familial Parkinson's disease. Movement Disorders, 2009, 24, 1125-1131.	2.2	45
43	Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Human Genetics, 2009, 124, 593-605.	1.8	410
44	Genomewide association study for onset age in Parkinson disease. BMC Medical Genetics, 2009, 10, 98.	2.1	104
45	Multiple step pattern as a biomarker in Parkinson disease. Parkinsonism and Related Disorders, 2009, 15, 506-510.	1.1	58
46	Clinical correlates of depressive symptoms in familial Parkinson's disease. Movement Disorders, 2008, 23, 2216-2223.	2.2	37
47	R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation. Movement Disorders, 2007, 22, 254-256.	2.2	8
48	Mutations in DJ-1 are rare in familial Parkinson disease. Neuroscience Letters, 2006, 408, 209-213.	1.0	45
49	Mutations in LRRK2 other than G2019S are rare in a north americanâ€"based sample of familial Parkinson's disease. Movement Disorders, 2006, 21, 2257-2260.	2.2	26
50	Verification of Self-Report of Zygosity Determined via DNA Testing in a Subset of the NAS-NRC Twin Registry 40 Years Later. Twin Research and Human Genetics, 2005, 8, 362-367.	0.3	61
51	Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet, The, 2005, 365, 410-412.	6.3	243
52	Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease. Movement Disorders, 2004, 19, 649-655.	2.2	33
53	Reliability of reported age at onset for Parkinson's disease. Movement Disorders, 2003, 18, 275-279.	2.2	29
54	Significant Linkage of Parkinson Disease to Chromosome 2q36-37. American Journal of Human Genetics, 2003, 72, 1053-1057.	2.6	158

#	Article	IF	Citations
55	Genome Screen to Identify Susceptibility Genes for Parkinson Disease in a Sample without parkin Mutations. American Journal of Human Genetics, 2002, 71, 124-135.	2.6	162
56	BMPR2 Haploinsufficiency as the Inherited Molecular Mechanism for Primary Pulmonary Hypertension. American Journal of Human Genetics, 2001, 68, 92-102.	2.6	521
57	Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature, 2001, 413, 488-494.	13.7	1,623
58	Heterozygous germline mutations in BMPR2, encoding a TGF-Î² receptor, cause familial primary pulmonary hypertension. Nature Genetics, 2000, 26, 81-84.	9.4	1,388